Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease
These data support the long-term efficacy and safety of non-medical ADA switching in IBD and will help inform patients and physicians in jurisdictions currently undergoing biosimilar switching.
Authors
- Thomas Hoang
- Marica Reise-Filteau
- Greg Rosenfeld (ORCID: https://orcid.org/0000-0002-4951-8818)
- Yvette Leung (ORCID: https://orcid.org/0000-0002-8699-4370)
- Brian Bressler (ORCID: https://orcid.org/0000-0003-4740-8209)
- Daniel Rosenfeld (ORCID: https://orcid.org/0000-0002-0784-7656)
- Harjot Bedi
- Jeremy Liu Chen Kiow (ORCID: https://orcid.org/0000-0003-2486-3647)
- Zhina Majdzadeh Ardekani
Institutions
- Western University (CA)
- University of British Columbia (CA)
- St. Paul's Hospital (CA)
- British Columbia Centre on Substance Use (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- St. Paul's Hospital (CA)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.3748/wjg.v30.i46.4904
- Citations
- 4
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.96